Thermo Fisher Scientific Announces $11.5Bn Buyout Of Qiagen
Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.
You may also be interested in...
Thermo Fisher has priced an offering of $2.2bn senior notes to pay for its planned acquisition of Qiagen. The news comes the same week, Qiagen confirmed Thierry Bernard as permanent CEO following the departure of former leader Peer Schatz.
Qiagen has secured funding from a US government agency to develop a new test kit for COVID-19.
NeuMoDx Molecular announced plans to develop a coronavirus test for its own high-throughput molecular diagnostics platform.